Journal of Drug Assessment
Volume 7, 2018 - Issue 1
Open access
859
Views
9
CrossRef citations to date
0
Altmetric
Oncology
Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis
Anand A. DalalNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA; View further author information
, Annie GuerinAnalysis Group, Inc, Montréal, QC, CanadaCorrespondence[email protected]
View further author information
, View further author information
Alex MutebiNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA; View further author information
& Kenneth W. CulverNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA; View further author information
Pages 21-27
|
Received 27 Nov 2017, Accepted 12 Feb 2018, Published online: 12 Mar 2018
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.